IRCT20181124041743N1 IRCT 2019-02-12 Shahid Beheshti University of Medical Sciences Botulinum toxin injection in pediatric population with spastic neuropathic bladder Botulinum toxin injection in pediatric population affected by spastic neuropathic bladder resistant to medical therapy 2018-11-30 anticipated 20 Complete https://irct.ir/trial/35487 interventional Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment. 2-3 Condition 1: Neurogenic bladder. Condition 2: Neurogenic bladder dysfunction due to cauda equina syndrom. Intervention group: Patients who have the inclusion criteria to enrol the study,first will undergo primary urodynamic study with DELPHIS IP,MODEL 94_RO1P_BT manufactured by LABORIE MEDICAL TECHNOLOGIES and interview with parents.Bladder volume and number of hours not demanding diaper change will be registered. After that Botox manufactured by Ipsen Biopharm Ltd UK with the amount of 10u/kg and maximal dose of 300units will be injected in Operating room under general anesthesia with rigid cystoscope by one surgeon.Site of injection is in detrusor muscles along with anterior and posterior far from trigon. Three months later, repeated urodynamic study with the same primary device and interview with parents will be done and bladder volume and hours not demanding diaper change will be recorded, respectively.. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is It is not decided yet